Introduction
Giant cell tumour (GCT) of bone is a rare neoplasm that accounts for approximately 5% of all primary bone tumours in adults, 1 occurring most commonly between 20 and 45 years of age and affecting males and females with equal frequency. 2 Although GCTs are generally considered to be benign tumours, they are aggressive and can metastasize to cause extreme morbidity. 3 -7 Distant metastases of GCT are uncommon, but 3% of cases have pulmonary metastases. 8 Local recurrence is 10 times more frequent than metastasis. 8, 9 The high recurrence rate associated with sacral GCT has been linked to the difficulty in diagnosis, large tumour volume, poorly defined tumour margins and the surgically inaccessible location of the lesions. 1, 2, 8 Sacral GCT is generally slow growing, with nonspecific symptoms. 2, 8 The chief symptom in most patients is local pain which, at times, radiates to the hips. 2 The nonspecific nature of symptoms often precludes early diagnosis and results in large lesion size at initial presentation. 1 
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the upper sacrum can compress the S1 nerve root, causing weakness in the gastrocnemius muscle. 8, 9 Tumours of the lower sacral region tend to present with pain, loss of bowel and bladder control, perineal numbness and sexual dysfunction. 8 Early diagnosis is important if patients are to receive effective treatment. Magnetic resonance imaging (MRI) and computed tomography (CT) scans allow precise visualization of the location and size of tumours and assist in diagnosis ( Fig. 1 ). 10 Karyotyping is useful for the classification of GCT and may provide insight into pathogenesis and treatment. 11 Telomeric fusion of chromosomes 13, 14 and 21 may serve as oncogenic events, promoting and sustaining the transformed GCT phenotype. 12 Telomeric instability is responsible for a large part of intratumour heterogeneity and can act as a precursor to subsequent clonal structural aberrations of chromosome 11 in GCT of bone. 13 Fineneedle aspiration biopsy is an effective tool for the differential diagnosis of sacral GCT, aneurysmal bone cyst, giant cell reparative granuloma, chondroblastoma and brown tumour of hyperparathyroidism. 14, 15 Giant cell tumour of the sacrum is a challenging problem because the local recurrence rate is higher than in any other skeletal location; 2, 16, 17 it has been shown to be as high as 33%. 9 En bloc resection is the treatment most effective at preventing recurrence. 18 Intralesional resection followed by intracavitary inactivation of the lesion is now more widely preferred by both physicians and patients compared with en bloc resection, which has several complications. A variety of adjuvant treatments following intralesional excision have been used for sacral GCT. These include intracavitary cryosurgery, radiotherapy, chemotherapy and selective arterial embolization. 18, 19 If complete resection is not possible, intralesional curettage is acceptable, although this is associated with a high recurrence rate. 18, 19 Some researchers have advocated cryosurgery as an intraoperative adjuvant. 18 This is successful in long bone lesions, but the optimal treatment and medical management of sacral GCT is not well established. The objective of this article is to review the current surgical and adjuvant treatment modalities available for the management of sacral GCT.
Literature search methodology
A search of the PubMed database was conducted on papers published between January 1960 and April 2011 using the terms 'giant cell tumour' and 'sacrum', or 'sacrectomy' and 'orthopaedic procedure'. Full text articles were retrieved where the abstract mentioned treatment modalities, operative technique, follow-up, recurrence rate or complications. The reference lists of these publications were manually reviewed, and the full text of articles that could be included in this review were obtained. Finally, reference lists were searched for additional potential publications. No attempt was made to locate any unpublished studies.
Studies were then reviewed based on the following criteria: (i) data reported from a case series or from a case-control study; (ii) primary lesions of the sacrum; (iii) the manuscript was written in English; (iv) the studies reported on more than five cases of sacral GCT; and (v) the studies described surgical treatment. In studies that included outcome assessment, data from the longest duration of follow-up were examined.
The key word search yielded a total of 207 articles, of which 47 were not in English. There were 76 case reports and 23 reviews, but two of these were also case series and met the inclusion criteria. There were two clinical trials, three letters, one radiological study, and three comparative studies. In 33 articles, only the abstract was in English. Of the remaining 21 articles, 14 did not assess surgical treatment or reported fewer than five cases of sacral GCT. All articles were read and reviewed by two authors (C.C.S. and H.L.). Details of the seven studies in which the outcome of surgery/treatment and/or adjuvant therapy was clearly described are included in Table 1 . 16,18 -23 
Surgical treatment PARTIAL OR COMPLETE RESECTION
The surgical techniques for resection of sacral GCT include intralesional, wide, marginal and radical excision such as total sacrectomy. The goals of surgery include maximal resection and preservation of neurological function. Local recurrence may depend more on the thoroughness of surgical treatment than on the intrinsic biology of the tumour, 24 and wide resection is the best treatment for sacral GCT. Several factors including anatomical characteristics, intraoperative blood loss and preservation of CC Shen, H Li, ZL Shi et al.
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nerve function often result in the use of an intralesional excision approach. An intralesional procedure gives better functional results with fewer complications than en bloc resection. 16, 18, 19, 25 Several adjuvant therapies including polymethyl methacrylate (PMMA), phenol and liquid nitrogen have been reported to minimize the risk of recurrence of these tumours. 18, 26 Cryotherapy results in a recurrence rate of 28.6% in sacral tumours and has complications related to necrosis of adjacent tissue. 18 Marcove et al. 18 reported that two of seven patients treated with curettage after cryosurgery, or planned limited excision with cryosurgery, developed radiologically detectable local recurrence. The periods from first treatment to recurrence were 7 and 10 months, respectively. Repeat curettage and cryosurgery resulted in the patients being disease free for 13.3 years and 9.7 years, respectively. 18 Phenol injection has been reported to result in a recurrence rate of 9% (median follow-up of 5 years) 27 or 25% (median follow-up of 11 years, lesion grafted with bone). 28 Curettage and phenol/PMMA inactivation yielded a reported recurrence rate of 6%. 26 Guo et al. 20 reported a 5-year local recurrence-free survival rate of 69.6%; the operative procedure of these cases was curettage for tumours located at S1 and S2 and planned translesional excision for caudal tumours (S3 and below). It was suggested that the relatively low recurrence rate could be attributed to effective control of intraoperative haemorrhage, partial resection and curettage instead of complete curettage, and the use of a hydrojet to excise the tumour in the eight patients.
Intralesional excision leads to a high incidence of local recurrence and difficulties in subsequent total surgical resection. 23, 29 Although potential neurological deficit and lumbosacral instability make en bloc sacrectomy less attractive, this procedure may provide a cure for sacral GCT. 23,29 -35 Given the poor outcome of recurrence, postoperative neurological functional deficits may be acceptable. Total and partial sacrectomy remain technically challenging because of the complexity of the operations and concomitant risks. 29, 31, 32 In a follow-up study of nine patients with sacral GCT, Martin and McCarthy 19 reported that two of six patients treated with preoperative arterial embolization and intralesional surgical resection developed recurrence, in contrast to two patients who were treated with en bloc resection and did not develop recurrence. The final patient was treated with serial arterial embolization alone, with good outcome. This study was limited due to the short duration of the follow-up, but en bloc excision or preoperative embolization followed by intralesional resection appear to be associated with good prognosis. 19 Complete removal of the tumour during the initial surgery is important for favourable prognosis because this minimizes the risk of recurrence, 18 but postoperative quality of life related to pelvic stability is also important. Instrumentation used for lumboiliac stabilization includes two L-shaped rods that are attached to pedicle screws in the lumbar spine (the Galveston technique). 36 Although this method has several biomechanical limitations, including suboptimal resistance of rotational and axial force that may subsequently lead to loosening and failure, it is a commonly used procedure. 30 Intraoperative bleeding during sacrectomy may be controlled by ligation of both the internal iliac artery and vein, and large transfusion volumes are required for pelvic bleeding. 20,29 -35,37,38 Better bleeding control could be achieved by ligation of the branches connecting to the external iliac vein, which may otherwise contribute to incomplete separation between the internal and external iliac veins. 29 -32 This technique helps to prevent pelvic vein laceration during a posterior approach. 39 Alternatively, a balloon dilation catheter for occlusion of the abdominal aorta could result in better intraoperative bleeding control.
SURGICAL APPROACHES
It is particularly important to select a surgical approach that allows thorough resection of the tumour. Several approaches can be adopted to remove a sacral GCT, and it is not clear which of these approaches improves the possibility of complete excision. The approaches to sacral tumours include posterior and anterior via the transabdominal or retroperitoneal path. 40 A rarely used pathway for distal sacral tumours is the perineal approach. 41 Several approaches are described for high-level sacral tumours, including a midline posterior, an ilioinguinal and posterior, and a combined anterior trans-or retroperitoneal and posterior approach. 29 The wide resection of a relatively benign sacral tumour is feasible via a combination of anterior and posterior approaches, and a combined extended ilioinguinal and posterior approach is effective and practical for the wide resection of a high-level sacral tumour. 42 A two-stage resection is advisable in some cases to achieve complete removal of large and aggressive sacral tumours. 22, 41 The first stage involves an anterior approach to free the anterior tumour from the pelvis, viscera and blood vessels. The second stage is a posterior sacrectomy, en bloc tumour resection and sacral reconstruction. Preoperative imaging (MRI or CT) and meticulous physical examination are helpful to estimate the features of the neoplasm. A posterior approach is preferred for nidus at S3 and below or lesions developing towards CC Shen, H Li, ZL Shi et al.
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the back, and an anterior approach for lesions above S3. 42 In an anteroposteriorly compromised case, a combined approach allows for the exposure of sacral circumferentia and the entire resection of the lesion.
SPINOPELVIC RECONSTRUCTION
Various spinopelvic reconstruction techniques have been used with variable results. 29,31 -35 Given the substantial risk of infection and hardware failure, 29, 32, 37 the benefit of reconstruction after total resection remains debatable. When major wound complications are taken into consideration, especially deep wound infection, some researchers do not advocate reconstructing the osseous defect after total sacrectomy. 42 -44 Pelvic stability after major amputation of the sacrum was evaluated by Gunterberg et al. 45 The pelvic ring was weakened by approximately 30% after resection of one third of the sacroiliac joints and associated ligamentous tissue, and the pelvic ring could be stable as long as half of the S1 vertebra was intact. 45 In other words, if S1 was compromised by tumour, reconstruction to stabilize the lumbar spine and ilium was favourable. Although the pelvis was weakened, the residual strength could support normal standing weight-bearing. Reconstruction after total sacrectomy might facilitate walking, 46 although this group did not try to implant bone grafts or hardware after total sacrectomy because of the high risk of major wound complications. In addition, Wuisman et al. 29 reported no significant differences in functional effect between patients who had reconstruction and those who did not. The iliolumbar muscle and ligaments produced a biological sling that stabilized the spine, eventually acting as a weight-bearing joint. 29 Reconstruction traditionally includes various combinations of bolts, screws, rods and grafts. The Galveston L-rod technique was used by Gokaslan et al. 30 to establish a bilateral liaison between the lumbar spine and ilia, with a threaded rod connecting the left and right ilia to re-establish the pelvic ring. Reconstruction promoted postoperative recovery and quality of life to some degree, but there were no significant differences in functional outcome between patients with and without instrumental reconstruction. 29
COMPLICATIONS
Intraoperative blood loss is the most common and remarkable complication of sacral GCT resection. The sacral blood supply derives mainly from the internal iliac and median sacral arteries, with anastomotic branches and accompanying veins forming the presacral venous plexus. A combined anterior and posterior approach for resection of large tumours of the cephalad part of the sacrum resulted in mean blood loss of 7 l (range 2 l -20 l) in spite of ligation of the internal iliac vessels. 42 Preoperative arterial embolization is an effective measure to limit intraoperative blood loss with satisfactory outcome. 16, 19, 20 Other methods for controlling blood loss include manipulative hypotensive anaesthesia, low-pressure anaesthesia, low temperature, embolization of the internal arterial vessels, ligation of the internal vein and artery or temporary blocking of the abdominal aorta. Effective control of the sacral supporting vessels during sacral osteotomy is important.
Extirpation of sacral tumours often leads to large and complicated defects with deep cavities, exposed viscera, and loss of the sacrum, bowel and bladder control, sexual function and weight-bearing joints. 46 In one study, total sacrectomy and reconstruction resulted in complete loss of bladder and CC Shen, H Li, ZL Shi et al.
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bowel control in all patients, 29 but these complications may be avoided by intralesional resection. The dimensions of the defect make bilateral gluteal myocutaneous advancement flaps, transpelvic vertical rectus abdominis myocutaneous (VRAM) flaps and free flaps useful for reconstruction. 47 -49 Bilateral gluteal myocutaneous advancement flaps can be considered in patients with intact gluteal musculature and vasculature who have not been treated with preoperative radiotherapy. 47 The use of transpelvic VRAM flaps is advocated in patients with a history of radiotherapy and damaged gluteal vessels. 48 In cases where bilateral gluteal myocutaneous advancement flaps or transpelvic VRAM flaps are not possible, free flaps (e.g. free latissimus dorsi myocutaneous flaps and free RAM flaps) should be considered. 49 -51 In terms of the preservation of neurological function, unilateral resection of sacral roots or preservation of at least the unilateral S3 root in bilateral or unilateral resection preserved bowel and bladder control in the majority of patients. 52 Additionally, preserving bilateral S1 nerve roots is important for maintaining the patient's normal gait and foot plantar flexion. 8, 52 Patients with unilaterally preserved S2 nerve roots are likely to lose bladder control but retain bowel control. 52
Adjuvant therapy PREOPERATIVE ARTERIAL EMBOLIZATION
Selective preoperative arterial embolization is worthwhile as an initial treatment modality for large sacral GCT, especially in light of the widely recognized mortality associated with alternative therapies. 22 Consultation between neurosurgeons, radiation oncologists and interventionalists will lead to greater application of embolization techniques, thereby enhancing the treatment of sacral tumours.
Embolization can be used to treat GCTrelated pain and can also serve as an adjuvant therapy to surgery or radiotherapy. 22,53 -56 Reossification is visible on postoperative CT images, and angiography reveals decreased vascularity. 53 -56 Immediate symptomatic improvement was observed in 14 of 18 patients treated with embolization, 21 with a local recurrence rate of 38.9%. Embolization techniques have aided the treatment of GCT, especially sacral GCT. In a similar way to malignant tumours, these benign lesions can be embolized prior to resection in order to reduce blood loss. 55 Treatment with embolization alone resolved symptoms, arrested tumour growth and prevented recurrence in four of five patients. 57 Similar results were seen in 14 of 18 patients with sacral GCT treated with serial embolization. 21 Serial embolization of these lesions was typically performed at 4-to 6-week intervals until symptomatic improvement or disappearance of tumour vascularity. Success of embolization was confirmed by postprocedure angiography, MRI or CT scanning. 21 Immediate symptomatic improvement was seen and tumour growth or symptomatic recurrence occurred in 43% of patients after 15 years. 21 These findings suggest that all sacral GCT patients, especially those with large lesions, may benefit from preoperative arterial embolization.
Most patients experience nausea, emesis, low-grade fever and pain after arterial embolization, with symptoms lasting 3 -7 days. 21, 53, 54 Ischaemic neuropathy, a potential complication of any pelvic embolization, can result in motor and sensory deficits in the pelvis and lower extremities. 21, 54 Thus, care must be taken to CC Shen, H Li, ZL Shi et al.
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identify and avoid embolization of the neurovascular anatomy. Rectal ischaemia can arise from superior haemorrhoidal artery embolization. Any embolization of sacral tumours may result in injury to nontargeted tissue including muscle infarction, or injury to the skin, colon or other organs. 54 Highly selective arterial embolization would help to limit tumour blood supply and avoid complications.
RADIOTHERAPY AND CHEMOTHERAPY
Adjuvant radiotherapy following conservative surgical management of sacral GCT has been shown to be of no benefit, 16 but some authors advocate its use after intralesional resection. 19, 42, 58 Radiotherapy has been used to treat sacral GCT, but recurrence rates of 15 -49% have been reported, and other complications may arise, including postradiation fibrosis and radiation-induced malignancy. 9, 16, 19, 59, 60 The estimated frequency of malignant transformation of GCTs is < 1% but, after irradiation, it is as high as 10%. 16, 60 Chakravarti et al. 61 reported five cases of sacral GCT treated with radiation at doses of 40 -70 Gy. Of these, two developed progression at 5 and 8 months, respectively, and both required surgery. The remaining three patients were disease free throughout follow-up (between 3 and 10 years). 61 A dose of 50 Gy was recommended in order to maximize local control. Leggon et al. 16 reported a 49% rate of local recurrence in patients with pelvic or sacral GCT treated with radiotherapy alone, and an 11% risk of radiation-induced sarcoma, but Chakravarti et al. 61 found only a 3% risk using pooled data. Improvements in radiotherapy targeting, in particular the use of intensity-modulated radiation, may prove beneficial for these tumours.
Radiotherapy should be used only in situations where the benefits are likely to outweigh the risks -for example, tumour control following multiple local recurrences.
Chemotherapy is not often used in the treatment of GCT, and no standard protocol exists for these tumours. Chemotherapy agents, including methotrexate, adriamycin and cyclophosphamide, which are used in the treatment of sarcomas, are sometimes used for GCT. 16, 62 Adjuvant chemotherapy with adriamycin may be effective in controlling local lesions that are not fully resectable. 16, 62 Comprehensive management of sacral GCT Preoperative embolization followed by intralesional resection produces a reasonably low recurrence rate with excellent preservation of neurological function and satisfactory resection of large sacral GCT. 19, 20 A flow diagram indicating the currently recommended regime for the management of sacral GCT is given in Fig. 2 .
Conclusions
Computed tomography scanning and MRI are useful for the early diagnosis of sacral GCT. Preoperative diagnosis can be made via CT-guided needle biopsy. Selective arterial embolization is appropriate as an initial therapy in some surgical resection candidates. Total sacrectomy or curettage have advantages and disadvantages, depending on the location of the tumour and needs of the patient, but en bloc excision is the surgical procedure of choice. The use of adjuvant radiotherapy and chemotherapy remains controversial, and should be studied further. Functional reconstruction is important in cases where the lesion is high in the sacrum, and should be evaluated preoperatively. Sacral GCT is relatively rare, but usually CC Shen, H Li, ZL Shi et al. Treatment of sacral GCT: a review lethal, and current treatment measures need to be improved. Determination of the optimum treatment for sacral GCT will require randomized controlled trials. Early diagnosis, complete surgical resection with tumour-free margins and comprehensive treatment should be emphasized for local control and good results.
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